ND108E is designed to restore synaptic function and cognitive performance in Alzheimer’s disease (AD) and other neurodegenerative conditions. Under HylNeuro™ platform, ND108E employs hyaluronic acid (HA) as a biologically active carrier across the blood-brain barrier (BBB).
Unlike amyloid- or tau-centric therapeutics, ND108E targets the mitochondria, which is recognized as a contributor to early cognitive decline. Through precise targeting to cortex and hippocampal neurons, ND108E delivers its payload directly to affected regions, avoiding systemic off-target toxicity
ND108E is a CNS-targeted HA conjugate designed to restore cognition in post-menopausal Alzheimer's patients.
• Preclinical Data: Reversal of learning and memory deficits in behavioral models
• Mechanism: Amyloid plaque reduction confirmed by PET imaging; increased spine density and restored ChAT activity
• Status: IND-enabling studies in progress